Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 studyDominique Farge, Karin Tarte, Christophe Martinaud et al.|The Lancet Rheumatology|2022Cited by 38
Heart and systemic sclerosis—findings from a national cohort studyAlexis F. Guédon, Sébastien Rivière, Fabrice Carrat et al.|Lara D. Veeken|2023Cited by 11
French protocol for the diagnosis and management of hematopoietic stem cell transplantation in autoimmune diseasesDominique Farge, Zora Marjanovic, G. Pugnet et al.|La Revue de Médecine Interne|2024Cited by 9
Mouth opening in systemic sclerosis: A longitudinal analysis from the French national cohort studyBenjamin Chaigne, Alexandre Bense, C. Agard et al.|Journal of Internal Medicine|2023Cited by 7
Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysisAlexis F. Guédon, Sébastien Rivière, Fabrice Carrat et al.|RMD Open|2024Cited by 4